New Indication for Pradaxa
RIDGEFIELD, Conn., November 23, 2015 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Pradaxa® (dabigatran etexilate mesylate) for the prophylaxis of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone hip replacement surgery.
Spreading the Word About Thrombosis
After fracturing her ankle and getting a cast, South African athlete Marie-Victoire Cumming began feeling extreme discomfort in her leg. What she didn't know was that she had a potentially life-threatening condition called deep vein thrombosis.